カテゴリ： GlobalData, アメリカ, 企業調査

Spectrum Pharmaceuticals Inc (SPPI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Spectrum Pharmaceuticals Inc (SPPI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9763
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：70
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Spectrum Pharmaceuticals Inc (Spectrum) is a biotechnology company that develops and commercializes a pipeline of late-stage clinical and commercial products with focus on hematology and oncology. The company’s marketed drugs include Fusilev (levoleucovorin); Folotyn (pralatrexate injection); Zevalin (ibritumomab tiuxetan); Marqibo (vincristine sulfate liposome injection), Beleodaq (belinostat) and Evomela (Captisol-Enabled Melphalan). It also has drugs in mid-to-late stage development, namely, Rolontis (eflapegrastim) for chemotherapy-induced neutropenia; Qapzola (apaziquone) for Intravesical Instillation; and Poziotinib for the treatment of various types of cancers. The company markets its products through direct sales force in the US and through distributors in Europe. Spectrum is headquartered in Henderson, Nevada, the US.

Spectrum Pharmaceuticals Inc (SPPI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
myTomorrows Enters into Agreement with Spectrum Pharma 14
Spectrum Pharma Enters into Agreement with Servier Canada 15
Eagle Pharma Enters into Agreement with Spectrum Pharma 16
Licensing Agreements 17
Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 17
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 18
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 20
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 21
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 23
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 24
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 26
Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 27
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 28
Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 29
Equity Offering 30
Spectrum Pharma Raises USD90.2 Million in Private Placement of Shares 30
Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32
Spectrum Pharma to Raise USD100 Million in Public Offeirng of Shares 33
Talon Therapeutics Completes Private Placement Of Preferred Stock For US$11 Million 34
Debt Offering 36
Spectrum Pharma Completes Private Placement Of Notes Due 2018 For US$100 Million 36
Acquisition 38
Spectrum Pharmaceuticals May Sell Itself 38
Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 39
Spectrum Pharma Completes Acquisition Of Allos Therapeutics For USD206 Million 41
Spectrum Pharmaceuticals Inc – Key Competitors 43
Spectrum Pharmaceuticals Inc – Key Employees 44
Spectrum Pharmaceuticals Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 46
Recent Developments 47
Financial Announcements 47
Aug 09, 2018: Spectrum Pharmaceuticals reports second quarter 2018 financial results and pipeline update 47
May 03, 2018: Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update 49
Mar 06, 2018: Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update 51
Nov 02, 2017: Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update 53
Aug 03, 2017: Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update 55
May 02, 2017: Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update 56
Mar 08, 2017: Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update 57
Corporate Communications 59
Oct 18, 2018: Spectrum Pharmaceuticals names Dr. Francois Lebel as chief medical officer 59
Feb 27, 2018: Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors 60
Dec 17, 2017: Spectrum Pharmaceuticals Announces Leadership Changes 61
Product News 62
12/04/2017: Spectrum Pharmaceuticals To Present Abstracts On MARQIBO At The 59th Annual Meeting Of The ASH in Atlanta, Georgia, December 9-12, 2017 62
06/02/2017: Spectrum Pharmaceuticals Announces Presentation on MARQIBO at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 63
06/02/2017: Spectrum Pharmaceuticals Highlights Clinical Data on FOLOTYN at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 64
Product Approvals 65
Sep 07, 2017: CASI Provides Update on MARQIBO 65
Clinical Trials 66
Jun 19, 2017: Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting 66
Other Significant Developments 67
Apr 30, 2018: Spectrum Pharmaceuticals announces corporate governance enhancements and board changes 67
Apr 27, 2018: Company Profile for Spectrum Pharmaceuticals 68
Mar 07, 2018: Spectrum Pharmaceuticals to present corporate update at the Cowen and Company 38th annual health care conference on March 13th 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Spectrum Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
myTomorrows Enters into Agreement with Spectrum Pharma 14
Spectrum Pharma Enters into Agreement with Servier Canada 15
Eagle Pharma Enters into Agreement with Spectrum Pharma 16
Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 17
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 18
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 20
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 21
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 23
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 24
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 26
Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 27
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 28
Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 29
Spectrum Pharma Raises USD90.2 Million in Private Placement of Shares 30
Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32
Spectrum Pharma to Raise USD100 Million in Public Offeirng of Shares 33
Talon Therapeutics Completes Private Placement Of Preferred Stock For US$11 Million 34
Spectrum Pharma Completes Private Placement Of Notes Due 2018 For US$100 Million 36
Spectrum Pharmaceuticals May Sell Itself 38
Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 39
Spectrum Pharma Completes Acquisition Of Allos Therapeutics For USD206 Million 41
Spectrum Pharmaceuticals Inc, Key Competitors 43
Spectrum Pharmaceuticals Inc, Key Employees 44
Spectrum Pharmaceuticals Inc, Other Locations 45
Spectrum Pharmaceuticals Inc, Subsidiaries 45
Spectrum Pharmaceuticals Inc, Joint Venture 46

List of Figures
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Spectrum Pharmaceuticals Inc (SPPI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Olympus Corporation：企業の戦略・SWOT・財務情報
    Olympus Corporation - Strategy, SWOT and Corporate Finance Report Summary Olympus Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Oceanteam ASA (OTS)：企業の財務・戦略的SWOT分析
    Oceanteam ASA (OTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mtr Corporation Ltd
    Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Galapagos NV：企業のM&A・事業提携・投資動向
    Galapagos NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Galapagos NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Tivo Corporation：戦略・SWOT・企業財務分析
    Tivo Corporation - Strategy, SWOT and Corporate Finance Report Summary Tivo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Prismic Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析
    Summary Prismic Pharmaceuticals Inc (Prismic Pharmaceuticals) is a pharmaceutical company that provides research and development of prescription drugs which has unique safety profiles. The company develops drugs for inflammatory diseases and oxidative stress disorders. It pipeline products are used …
  • HCA Healthcare, Inc.：戦略・SWOT・企業財務分析
    HCA Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report Summary HCA Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Meredith Corporation：企業の戦略・SWOT・財務分析
    Meredith Corporation - Strategy, SWOT and Corporate Finance Report Summary Meredith Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • TreeHouse Foods, Inc.：企業のM&A・事業提携・投資動向
    TreeHouse Foods, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TreeHouse Foods, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Connecticut Municipal Electric Energy Cooperative：企業の戦略的SWOT分析
    Connecticut Municipal Electric Energy Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competi …
  • Medicago Inc：企業のM&A・事業提携・投資動向
    Medicago Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medicago Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Syndax Pharmaceuticals Inc (SNDX)：企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • Shionogi & Co., Ltd.：企業の戦略・SWOT・財務情報
    Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • National Fuel Gas Company：企業の戦略・SWOT・財務情報
    National Fuel Gas Company - Strategy, SWOT and Corporate Finance Report Summary National Fuel Gas Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Endava Limited
    Endava Limited - Strategy, SWOT and Corporate Finance Report Summary Endava Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Industrial Bank Co., Ltd.
    Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Nanoco Group Plc (NANO)：企業の財務・戦略的SWOT分析
    Nanoco Group Plc (NANO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Otsuka Pharmaceutical Co., Ltd.：企業のM&A・事業提携・投資動向
    Otsuka Pharmaceutical Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Otsuka Pharmaceutical Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Illinois Municipal Electric Agency：企業の戦略的SWOT分析
    Illinois Municipal Electric Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Partners Group Holding AG (PGHN)：企業の財務・戦略的SWOT分析
    Summary Partners Group Holding AG (Partners Group) is a private market investment manager that offers private equity and investment services. The company manages investment programs and customized portfolios for institutional investors such as insurance companies, pension funds, and sovereign wealth …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆